DYNAVAX WKN: A12EV9 ISIN: US2681582019 Kürzel: DVAX Forum: Aktien Thema: Hauptdiskussion

Wird Zeit den EK wieder zu sehen....

Dynavax Reports Third Quarter 2022 Financial Results https://www.prnewswire.com/news-releases/dynavax-reports-third-quarter-2022-financial-results-301667261.html • Q3 2022 total revenue of $167.7 million, up 55% from $108.3 million for Q3 2021 • HEPLISAV-B® vaccine net product revenue of $37.5 million, up 65% from $22.7 million for Q3 2021 • CpG 1018® adjuvant net product revenue of $126.3 million, up 50% from $84.3 million for Q3 2021 • Reiterates guidance for full-year CpG 1018 adjuvant net product revenues of between $550 million and $600 million  • On track for a second consecutive year of profitability

Langsam nervts

Langsam müsste doch mal die Gegenbewegung starten

Ich hoffe, das Vertrauen zahlt sich irgendwann aus 😁

Wo ist die nächste Unterstützung?

..in einer Woche von 17 so runter 🙃

Des is echt grass ..keinerlei Infos zu finden aber doch wieder so ein Abgang 🙄🥴

Also was hier immer abgeht, ohne das man was findet...

Über 7 % minus. Gibts Neuigkeiten?

Alles zu seiner Zeit 😉

Wenn ich sehe, was zur Zeit wieder für Schrott gehyped wird, 40% in einer Woche steigt und so eine Perle geht mehr oder weniger seitwärts.

Dynavax GAAP EPS of $0.87 beats by $0.65, revenue of $256.46M beats by $105.47M https://seekingalpha.com/news/3867502-dynavax-gaap-eps-of-0_87-beats-0_65-revenue-of-256_46m-beats-105_47m • Dynavax press release (NASDAQ:DVAX): Q2 GAAP EPS of $0.87 beats by $0.65. • Revenue of $256.46M (+386.0% Y/Y) beats by $105.47M. • Cash and Marketable Securities.  Cash and marketable securities were $518.2 million as of June 30, 2022. • 2022 Financial Guidance: Full-year CpG 1018 adjuvant net product revenues of between $550 million and $600 million, with an associated gross margin anticipated to be approximately 60% • Research and development expenses to be between approximately $50-$60 million • Selling, general and administrative expenses to be between approximately $130-$140 million • Interest expense of approximately $7 million

🥳

Dynavax Reports Second Quarter 2022 Financial Results https://www.prnewswire.com/news-releases/dynavax-reports-second-quarter-2022-financial-results-301600280.html • Q2 2022 total revenue of $256.5 million, up 386% from $52.8 million for Q2 2021 • HEPLISAV-B® vaccine net product revenue of $32.7 million, up 139% from $13.7 million for Q2 2021 • CpG 1018® adjuvant net product revenue of $222.6 million, up 471% from $39.0 million for Q2 2021 • On track for second consecutive year of profitability ...